Common variable immunodeficiency (CVID) is a heterogeneous group of disorders in which the immune system produces insufficient amounts of functional antibodies. It is characterized by persistently reduced blood concentrations of immunoglobulin G (IgG), usually accompanied by reduced immunoglobulin A (IgA), immunoglobulin M (IgM), or both, and impaired antibody responses. CVID is classified as a primary immunodeficiency, also termed an inborn error of immunity. Its manifestations range from recurrent respiratory infections to autoimmune disease, chronic inflammation, and abnormal lymphoid tissue growth. The name describes variability between affected individuals, not a disorder that necessarily fluctuates between normal and abnormal immunity.
Epidemiology and presentation
CVID is among the more frequently recognized symptomatic primary antibody deficiencies. Estimates of its prevalence vary across populations and diagnostic systems, commonly falling between approximately 1 in 25,000 and 1 in 50,000 people. Limited recognition and access to immunological testing affect these estimates.
Symptoms can begin in childhood or adulthood, and diagnosis may follow years of recurrent illness. Both sexes are affected. Although a minority of cases occur in families with other antibody deficiencies, most affected individuals have no clearly established family history.
CVID is generally not diagnosed before about four years of age because immune maturation and transient childhood antibody deficiencies can complicate interpretation. Earlier or unusually severe presentations may instead indicate a more specifically defined immune disorder.
Biological basis
Antibodies are proteins that recognize pathogens and other foreign substances. They support infection control through mechanisms including neutralization and the marking of microbes for destruction.
In many people with CVID, B cells are present in the blood but do not mature normally into antibody-secreting plasma cells or develop an adequate population of class-switched memory B cells. These memory cells normally contribute to sustained, specialized antibody responses after infection or immunization.
The defect is not always restricted to B cells. Abnormalities in T cells, immune signaling, and immune regulation occur in some patients. These findings help explain why CVID can involve both inadequate protection against infection and inappropriate immune activity against the body’s own tissues.
Genetic heterogeneity
CVID does not have a single genetic cause. In most people meeting clinical criteria, no single causative genetic alteration is identified. Some have disease-causing variants in genes involved in B-cell function, communication between immune cells, or immune regulation.
Modern genetic testing can reclassify some CVID-like presentations as specific monogenic disorders. This distinction can be important because particular disorders have different associated complications and, in some cases, different treatment options. Conversely, finding a genetic variant does not by itself establish that the variant caused the antibody deficiency.
Clinical manifestations
Recurrent infections
The most characteristic infections involve the sinuses, middle ears, bronchi, and lungs. Repeated episodes of otitis media and pneumonia may occur, often involving encapsulated bacteria such as Streptococcus pneumoniae and Haemophilus influenzae.
Repeated or persistent lower respiratory infections can lead to bronchiectasis, an irreversible widening of the airways associated with impaired mucus clearance and further infections.
Gastrointestinal infections also occur. Giardia duodenalis is a recognized cause of persistent diarrhea in people with antibody deficiency. Other infections may be prolonged or recurrent. Severe opportunistic infections are less typical of uncomplicated antibody deficiency and can indicate additional defects in cellular immunity or another immune disorder.
Autoimmune and inflammatory complications
Some individuals first present with autoimmune disease rather than recurrent infection. Autoimmune destruction of platelets or red blood cells is a characteristic manifestation; the latter can cause autoimmune hemolytic anemia.
Chronic inflammatory complications can affect the lungs, gastrointestinal tract, liver, and other organs. CVID-associated enteropathy may cause diarrhea, weight loss, and impaired nutrient absorption. Its intestinal changes can resemble celiac disease, but the underlying process and response to dietary exclusion are not necessarily the same.
Some patients develop granulomas: organized collections of immune cells within tissues. A recognized pulmonary complication is granulomatous–lymphocytic interstitial lung disease, which involves inflammatory and lymphoid changes in the lungs. It is distinct from infection-related airway damage, although both can coexist.
Lymphoid enlargement and malignancy
Enlargement of lymph nodes and the spleen can occur because of nonmalignant immune-cell proliferation. These findings do not necessarily indicate cancer.
Nevertheless, CVID is associated with an increased risk of certain malignancies, particularly lymphoma and stomach cancer. Reported risk estimates differ between patient cohorts. Persistent infection, chronic inflammation, and impaired immune regulation may contribute.
Diagnosis
CVID is a diagnosis based on clinical and laboratory findings together with the exclusion of alternative explanations. No single test establishes it in every case.
Common elements of diagnostic assessment include:
- Persistently low immunoglobulin concentrations: IgG is substantially below the age-adjusted reference range, usually with low IgA and sometimes low IgM. Measurements are generally repeated.
- Impaired antibody function: testing may show inadequate production of specific antibodies following selected vaccines.
- Immune-cell characterization: blood testing can measure B-cell and T-cell populations, including class-switched memory B cells.
- Exclusion of secondary causes: low antibody concentrations can result from certain medicines, blood cancers, or loss of proteins through the kidneys or gastrointestinal tract.
- Assessment for alternative primary immune disorders: profound T-cell deficiency or a characteristic genetic finding may support a different diagnosis.
Diagnostic frameworks differ in details. Some require clinical manifestations and reduced IgA as well as IgG; some allow particular B-cell abnormalities as an alternative to demonstrating poor vaccine responses. Antibody deficiency alone therefore does not automatically establish CVID.
The differential diagnosis includes other primary antibody deficiencies and secondary immunodeficiency. Distinguishing persistent CVID from transient antibody deficiency is especially important in children.
Antibody-based tests for infections and autoimmune conditions can be difficult to interpret because affected individuals may not produce the expected antibodies. Immunoglobulin replacement can further complicate interpretation by introducing antibodies from donors.
Treatment and clinical management
Immunoglobulin replacement
The principal treatment for clinically significant CVID is immunoglobulin replacement therapy, administered intravenously or subcutaneously. These preparations contain pooled donor IgG and provide passive protection against a broad range of pathogens.
Replacement substantially reduces serious bacterial infections, particularly pneumonia. It does not restore normal antibody production, fully replace mucosal IgA, or reliably prevent autoimmune and inflammatory complications. Treatment is usually long term, with regimens individualized according to infection history, clinical response, and measured IgG levels.
Infection control and organ complications
Antibiotics are used to treat bacterial infections, and preventive antibiotic regimens are used in selected cases. Established bronchiectasis may also require airway-clearance measures and respiratory care.
Autoimmune cytopenias, inflammatory lung disease, enteropathy, and other complications may require immunosuppressive treatment. Such treatment can reduce immune-mediated injury but may also increase susceptibility to infection, making management more complex than antibody replacement alone.
Hematopoietic stem cell transplantation is not routine treatment for CVID. It has been used in selected severe cases, particularly where life-threatening immune dysregulation or a more specifically defined immune disorder is present.
Clinical course and prognosis
The course of CVID varies widely. Some individuals mainly experience infections that become much less frequent with immunoglobulin replacement. Others develop progressive lung damage, gastrointestinal disease, liver disease, autoimmune complications, or malignancy.
Long-term outcomes depend not only on infection control but also on the extent of organ damage and immune dysregulation. Noninfectious complications are important causes of illness and reduced survival, and can progress despite adequate replacement IgG concentrations.